resminostat Report issue

Small molecule Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Resminostat is an orally bioavailable inhibitor of histone deacetylases (HDACs), of which inhibitors are antineoplastic agents.   Wikipedia

Chemistry

  • SMILES: CN(C)Cc1ccc(S(=O)(=O)n2ccc(/C=C/C(=O)NO)c2)cc1
  • InChIKey: FECGNJPYVFEKOD-VMPITWQZSA-N
  • Mol. Mass: 349.41
  • ALogP: 1.31
  • ChEMBL Molecule:
    resminostat  
More Chemistry

Pharmacology

Alternative names

4sc-201 | ras2410 | ras 2410 | ras-2410 | resminostat

Organizations (12)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (1)


 

Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Carcinoma, Hepatocellular (Phase 2)

Colorectal Neoplasms (Phase 1/Phase 2)

Glomerulonephritis, IGA (Phase 4)

Hodgkin Disease (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Mycosis Fungoides (Phase 2)

Neoplasms ()

Sezary Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue